CJC-1295 research guide for Yardibi. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
For anyone in Yardibi searching for CJC-1295, the key fact to understand is that this compound is available only through an online research supply market. This matters because CJC-1295 quality differs enormously across the market — from verified research-grade material to mislabeled or underdosed compounds — and the vendor controls every quality variable. Vendors worth sourcing from openly share batch-matched Certificates of Analysis documenting HPLC chromatograms, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the exact batch you are purchasing. This guide guides Yardibi researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
How CJC-1295 Works — Mechanisms & Research
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Yardibi comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
CJC-1295 Purchasing Guide
Before assessing any particular supplier, establish a quality benchmark — so you can tell whether a COA is complete and credible. When reviewing a CJC-1295 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are at acceptable levels for the intended application. Warning signs in CJC-1295 vendor evaluation: prices more than 30-40% below standard market rates, unclear production details, no community presence, and COAs that do not include endotoxin results. Keep lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the amount needed for the near-term protocol and return unused portion to the freezer.
Order CJC-1295 — ships to Yardibi
COA-verified · International tracking · Research grade
All use of CJC-1295 in Yardibi or anywhere is research use only — this compound is not approved for clinical human use, and all handling should adhere to research compound handling standards. Reconstitute CJC-1295 with bacteriostatic water at a concentration matched to your dosing requirements; a standard 5mg in 2mL gives a 2.5mg/mL solution — equivalent to 25mcg per unit on an insulin syringe. Bacterial endotoxin contamination is the primary safety concern unique to this class of compound — verify endotoxin testing is included in the batch-specific COA before any injectable research application. The research literature on CJC-1295 should be studied thoroughly before designing any protocol — study designs, dosing ranges, and outcome measures vary significantly and conclusions do not uniformly extrapolate.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
